AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed solid tumor
• •* Advanced, metastatic, or recurrent disease
• •* No curative therapy exists
• •Measurable or evaluable disease
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •WHO 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Absolute granulocyte count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hemoglobin at least 9 g/dL
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's syndrome)
• •SGOT OR SGPT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
• •Renal:
• •Creatinine no greater than 1.5 mg/dL
• •Creatinine clearance at least 60 mL/min
• •Other:
• •No unstable or severe concurrent medical condition that would preclude study participation
• •No sociological or familial condition that would preclude study compliance
• •No psychological or addictive disorder that would preclude study compliance
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy and recovered
• •No prior radiotherapy to more than 40% of bone marrow
• •Surgery:
• •Not specified
• •Other:
• •At least 2 weeks since prior blood transfusions
• •At least 4 weeks since prior investigational agent and recovered
• •No prior glycinamide ribonucleotide formyltransferase (GARFT) inhibitor
• •No concurrent extradietary folate supplements
• •No concurrent allopurinol
• •No other concurrent anticancer or investigational agents